Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
|Poll|March 17, 2020
COVID-19: What's Your Impression?
Author(s)Laurie Martin
In this time of uncertainty, sometimes we need to refocus on what’s important. Take a deep breath, and then tell us, what do you think of when you see this image? An image IQ.
Advertisement
In this time of uncertainty, sometimes we need to refocus on what’s important. Take a deep breath, and then tell us, what do you think of when you see this image?
Advertisement
Related to this article
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Don't miss out on these CME articles! Test your knowledge here.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Makes Us Human? The Role of Psychiatry and the Future DSM
2
The First Ever Treatment-Resistant Depression Awareness Day
3
Relief Is Not Free: A Case Study of Athlete Cannabis Use
4
How Best to Manage Treatment-Resistant Depression
5